ESR1 and breast cancer: In fact, the progression to a more aggressive, endocrine-resistant breast cancer phenotype can be attributed to a positive cross-talk between ER and NF-κB activation, suggesting that these two transcription factors cooperate to upregulate the expression of several genes involved in cell survival and chemoresistance [60].